IPSC Century Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IPSC

Price (delayed)

$3.02

Market cap

$195.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.3

Enterprise value

$193.1M

Highlights
The quick ratio has increased by 17% since the previous quarter but it has declined by 8% year-on-year
The debt has declined by 4.7% year-on-year but it has grown by 2.5% since the previous quarter
The revenue has dropped by 57% year-on-year and by 10% since the previous quarter
Century Therapeutics's gross profit has plunged by 57% YoY and by 10% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of IPSC
Market
Shares outstanding
64.82M
Market cap
$195.75M
Enterprise value
$193.1M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.98
Price to sales (P/S)
80.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
86.4
Earnings
Revenue
$2.24M
EBIT
-$134.25M
EBITDA
-$122.4M
Free cash flow
-$102.08M
Per share
EPS
-$2.3
Free cash flow per share
-$1.72
Book value per share
$3.09
Revenue per share
$0.04
TBVPS
$6.08
Balance sheet
Total assets
$360.69M
Total liabilities
$175.94M
Debt
$46.66M
Equity
$184.75M
Working capital
$159.15M
Liquidity
Debt to equity
0.25
Current ratio
9.92
Quick ratio
9.79
Net debt/EBITDA
0.02
Margins
EBITDA margin
-5,476.7%
Gross margin
100%
Net margin
-6,115.1%
Operating margin
-6,556.9%
Efficiency
Return on assets
-33.5%
Return on equity
-58.9%
Return on invested capital
-36.6%
Return on capital employed
-39.2%
Return on sales
-6,006.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IPSC stock price

How has the Century Therapeutics stock price performed over time
Intraday
0.67%
1 week
4.86%
1 month
-18.38%
1 year
-5.63%
YTD
-9.04%
QTD
-27.75%

Financial performance

How have Century Therapeutics's revenue and profit performed over time
Revenue
$2.24M
Gross profit
$2.24M
Operating income
-$146.55M
Net income
-$136.67M
Gross margin
100%
Net margin
-6,115.1%
Century Therapeutics's operating margin has shrunk by 155% YoY and by 20% QoQ
The net margin has dropped by 143% year-on-year and by 18% since the previous quarter
The revenue has dropped by 57% year-on-year and by 10% since the previous quarter
Century Therapeutics's gross profit has plunged by 57% YoY and by 10% from the previous quarter

Growth

What is Century Therapeutics's growth rate over time

Valuation

What is Century Therapeutics stock price valuation
P/E
N/A
P/B
0.98
P/S
80.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
86.4
The EPS has declined by 5% since the previous quarter
The equity has declined by 39% year-on-year and by 16% since the previous quarter
IPSC's price to book (P/B) is 21% higher than its last 4 quarters average of 0.8
The revenue has dropped by 57% year-on-year and by 10% since the previous quarter
The price to sales (P/S) is 51% higher than the last 4 quarters average of 52.9

Efficiency

How efficient is Century Therapeutics business performance
The return on sales has dropped by 141% year-on-year and by 19% since the previous quarter
Century Therapeutics's ROE has plunged by 55% YoY and by 19% from the previous quarter
Century Therapeutics's return on assets has decreased by 33% YoY and by 14% QoQ
The ROIC has contracted by 20% YoY and by 13% from the previous quarter

Dividends

What is IPSC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IPSC.

Financial health

How did Century Therapeutics financials performed over time
Century Therapeutics's total assets is 105% higher than its total liabilities
Century Therapeutics's total assets has decreased by 26% YoY and by 9% QoQ
The current ratio has grown by 17% from the previous quarter but it has contracted by 7% YoY
The debt is 75% smaller than the equity
IPSC's debt to equity has soared by 56% year-on-year and by 19% since the previous quarter
The equity has declined by 39% year-on-year and by 16% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.